This study tests an experimental drug called CVM-1118 in 34 people with advanced neuroendocrine tumors that have not responded to standard treatments. The goal is to see if the drug can slow tumor growth or shrink tumors. Participants take the drug by mouth, and their progress is…
Phase: PHASE2 • Sponsor: TaiRx, Inc. • Aim: Disease control
Last updated May 14, 2026 12:02 UTC